SCHEMBL3727747

SCHEMBL3727747

CCOC(=O)C(CCOC(=O)c1ccc(OC(=O)c2ccccc2-c2ccc(C(F)(F)F)cc2)cc1)(C(=O)OCC)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.39
PDCD1 Q15116 1/20 0.38
CD274 Q9NZQ7 1/20 0.38
MTTP P55157 5/20 0.38
SCN1A P35498 2/20 0.38
SCN2A Q99250 2/20 0.38
SCN3A Q9NY46 2/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ELANE P08246 2/20 0.38
PRTN3 P24158 2/20 0.38
LMNA P02545 1/20 0.37
GPR119 Q8TDV5 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3737474 0.88 MTTP (0.41) PDK2CYP2C19GAAPDCD1CD274
SCHEMBL3726876 0.86 SMN1; SMN2 (0.48) GAAMTTPNPC1MAPTRAB9A
SCHEMBL3727750 0.86 MTTP (0.37) CYP2C19CYP1A2CYP3A4GAAMTTP
SCHEMBL3734465 0.82 MAPT (0.41) MAPTELANEPRTN3LMNA
SCHEMBL3737489 0.81 MTTP (0.56) CYP1A2MTTPNPC1RAB9A
SCHEMBL3725953 0.81 PDCD1 (0.40) PDCD1CD274MTTPMAPTGPR119
SCHEMBL27622150 0.79 SMN1; SMN2 (0.47) GAAMTTPNPC1MAPTRAB9A
SCHEMBL3727582 0.76 MTTP (0.48) GAAMTTPMAPTSMN1; SMN2LMNA
SCHEMBL3737476 0.76 MTTP (0.48) MTTPSCN1ASCN2ASCN3A
SCHEMBL3722371 0.75 PPARD (0.40) PDK2CYP2C19CYP1A2MTTPNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. 2010-06-24 US claimed
US-20050075367-A1 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-04-07 US claimed
EP-1479666-A1 ESTER COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-11-24 EP claimed
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF JAPAN TOBACCO INC. 2010-06-24 US disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 US disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 US disclosed
US-7625948-B2 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2009-12-01 US disclosed
US-20050075367-A1 Ester compound and medicinal use thereof JAPAN TOBACCO INC. (JP) 2005-04-07 US disclosed
EP-1479666-A1 ESTER COMPOUND AND MEDICINAL USE THEREOF JAPAN TOBACCO INC. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075367-A1 Ester compound and medicinal use thereof LIPC, CES1, MTTP PDK2 2497/4885CYP2C19 551/4885CYP1A2 450/4885
US-20100158996-A1 ESTER COMPOUND AND MEDICAL USE THEREOF LIPC, CES1, MTTP PDK2 2711/4885CYP2C19 523/4885CYP1A2 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.